262 related articles for article (PubMed ID: 35919193)
1. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
Kawashima S; Joachim K; Abdelrahim M; Abudayyeh A; Jhaveri KD; Murakami N
Korean J Transplant; 2022 Jun; 36(2):82-98. PubMed ID: 35919193
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
4. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review.
d'Izarny-Gargas T; Durrbach A; Zaidan M
Am J Transplant; 2020 Sep; 20(9):2457-2465. PubMed ID: 32027461
[TBL] [Abstract][Full Text] [Related]
7. Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases.
Kubiatowski T; Nicoś M; Krawczyk P
Front Oncol; 2020; 10():568081. PubMed ID: 33330040
[TBL] [Abstract][Full Text] [Related]
8. Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.
Van Meerhaeghe T; Murakami N; Le Moine A; Brouard S; Sprangers B; Degauque N
Clin Kidney J; 2024 Apr; 17(4):sfae061. PubMed ID: 38606169
[TBL] [Abstract][Full Text] [Related]
9. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
Hu B; Yang XB; Sang XT
Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in liver transplant: a case series.
Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss.
Wang T; Chen Z; Liu Y; Jia Y; Ju W; Chen M; Zhao Q; Wang D; Guo Z; Tang Y; He X
Liver Transpl; 2023 Jun; 29(6):598-606. PubMed ID: 36747346
[TBL] [Abstract][Full Text] [Related]
12. Tri-Site Academic Center Experience with Immunotherapy for Metastatic Skin Cancer in Solid Organ Transplant Patients.
Berman HS; Degesys CA; Tolaymat L
South Med J; 2023 Feb; 116(2):220-224. PubMed ID: 36724539
[TBL] [Abstract][Full Text] [Related]
13. Interventions for preventing thrombosis in solid organ transplant recipients.
Surianarayanan V; Hoather TJ; Tingle SJ; Thompson ER; Hanley J; Wilson CH
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD011557. PubMed ID: 33720396
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Maggiore U; Palmisano A; Buti S; Claire Giudice G; Cattaneo D; Giuliani N; Fiaccadori E; Gandolfini I; Cravedi P
Transpl Int; 2021 Dec; 34(12):2442-2458. PubMed ID: 34555228
[TBL] [Abstract][Full Text] [Related]
15. Advances and effectiveness of the immunotherapy after liver transplantation.
Vulasala SSR; Onteddu NK; Kumar SP; Lall C; Bhosale P; Virarkar MK
World J Gastrointest Surg; 2022 Jun; 14(6):629-631. PubMed ID: 35979423
[TBL] [Abstract][Full Text] [Related]
16. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade for organ-transplant recipients with cancer: A review.
Rünger A; Schadendorf D; Hauschild A; Gebhardt C
Eur J Cancer; 2022 Nov; 175():326-335. PubMed ID: 36191571
[TBL] [Abstract][Full Text] [Related]
18. Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review.
Miao K; Zhang L
Interdiscip Sci; 2021 Dec; 13(4):801-814. PubMed ID: 34152556
[TBL] [Abstract][Full Text] [Related]
19. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
20. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
